Business Context and Reporting Period
Company: Dogwood Therapeutics, Inc. (DWTX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 9, 2026 (Earliest event reported)
Reporting Period: Events occurring between January 9, 2026, and January 13, 2026.
The filing details a capital raise via a registered direct offering and concurrent private placement, as well as the termination of a prior at-the-market offering program.
Key Financial Metrics and Capital Structure
Capital Raise (Registered Direct Offering & Private Placement):
- Gross Proceeds: Approximately $12.5 million (before fees and expenses).
- Common Stock Issued: 2,338,948 shares at $2.85 per share.
- Pre-funded Warrants: 2,047,089 warrants issued at a combined price of $2.8499 per warrant (exercise price $0.0001).
- Common Stock Warrants: 4,386,037 warrants issued (exercise price $3.28; exercisable for 5.5 years pending stockholder approval).
- Placement Agent Fees: 7.0% of aggregate gross proceeds plus up to $75,000 in expense reimbursement.
- Closing Date: January 13, 2026.
Terminated Offering Program:
- Program: At-the-Market (ATM) offering with Northland Securities, Inc.
- Total Capacity: $8,558,712.
- Proceeds Realized: $89,792 prior to termination.
- Termination Date: January 9, 2026 (No termination penalties incurred).
Other Financial Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes Versus Prior Period
This filing represents a discrete capital event rather than a periodic financial comparison. Material changes include:
- Equity Dilution: Immediate issuance of approximately 2.34 million shares and the potential issuance of up to 6.43 million additional shares via warrants.
- Capital Availability: Shift from an ATM program (which yielded minimal proceeds) to a lump-sum registered direct offering expected to raise $12.5 million.
- Ownership Structure: Introduction of beneficial ownership limitations (9.99% for Pre-funded Warrants; 4.99% for Common Stock Warrants) for the investor.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- The Company announced the offering via a press release on January 12, 2026.
- The filing contains forward-looking statements regarding the Company's intent and expectations, which are not guaranteed to occur.
Risks and Contingencies:
- Stockholder Approval: Exercise of the Common Stock Warrants is subject to approval by the Company's stockholders.
- Registration Rights: The Company must file a registration statement for the resale of shares within 20 calendar days of closing and use best efforts to have it effective within 60 days (or 75 days if fully reviewed).
- Ownership Caps: Investors cannot exercise warrants if doing so would cause them to beneficially own more than the specified thresholds (9.99% or 4.99%).
- Liquidity Restrictions: Private Warrants and underlying shares are unregistered and may not be sold in the U.S. except pursuant to an effective registration statement or exemption.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received (expected ~$12.5 million).
- Confirm the status of the stockholder vote required to enable exercise of the Common Stock Warrants.
- Review the full text of the Purchase Agreement (Exhibit 10.1) for specific redemption rights or anti-dilution provisions.
- Monitor the filing of the registration statement for resale of shares as required by the Registration Rights Agreement.
- Assess the impact of the 7.0% placement fee and expenses on the net cash proceeds available for operations.